Bristol-Myers reports Phase II Sprycel data

BMY said interim data from a Phase II trial to treat chronic myelogenous leukemia showed that 35% of Gleevec-resistant or -intolerant patients given Sprycel dasatinib experienced a major cytogenetic response in the first three months, compared with 29% of those given an increased dose of Gleevec. The trial was not powered to show statistical significance.

Crossover was permitted in the event of disease progression or treatment intolerability. In the U.S. and Canadian trial, 6% of Sprycel patients crossed over, vs. 73% of Gleevec patients. ...